Literature DB >> 18690358

Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.

Alex Gatt1, Joost J van Veen, Anita M Woolley, Steve Kitchen, Peter Cooper, Michael Makris.   

Abstract

Even though new anticoagulants are being devised with the notion that they do not require regular monitoring, when bleeding occurs, it is important to have an antidote and a reliable test to confirm whether the anticoagulant effects are persisting. We examined the effects of five heparinoids, unfractionated heparin (UFH), tinzaparin, enoxaparin, danaparoid and fondaparinux on the traditional APTT and anti-Xa assays as well as on the calibrated automated thrombogram (CAT). We also studied the ability of protamine sulphate (PS), NovoSeven, FEIBA and FFP to reverse maximum anticoagulation induced by the different heparinoids. The CAT was the only test to detect the coagulopathy of all the anticoagulants. PS produced complete reversal of UFH, and this could be monitored with all three tests. Tinzaparin can also be completely neutralised in vitro with high doses of PS, but the maximum enoxaparin reversal achieved with PS is only approximately 60%. Fondaparinux does not significantly affect the APTT and PS has no significant effect on its reversal. Only NovoSeven was able to correct the fondaparinux induced CAT abnormalities whilst having no effect on the anti-Xa level. None of the reversal agents was very effective in danaparoid spiked plasma but NovoSeven, at high dose, increased the ETP by 40% and reduced the anti-Xa level from 0.93 to 0.78 IU/ml. We conclude that the CAT is superior to the traditional coagulation tests in that it not only detects the coagulopathy of all the heparinoids but can be also be used to monitor their reversal.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690358

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  12 in total

1.  Decline in platelet microparticles contributes to reduced hemostatic potential of stored plasma.

Authors:  Nena Matijevic; Yao-Wei W Wang; Vadim Kostousov; Charles E Wade; K Vinod Vijayan; John B Holcomb
Journal:  Thromb Res       Date:  2011-03-21       Impact factor: 3.944

Review 2.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives.

Authors:  Steen Husted; Freek W A Verheugt; Willemijn J Comuth
Journal:  Drug Saf       Date:  2016-01       Impact factor: 5.606

4.  Alterations of platelet function and clot formation kinetics after in vitro exposure to anti-A and -B.

Authors:  Majed A Refaai; Jessie Carter; Kelly F Henrichs; Donna C Davidson; Stephen J Pollock; Ann E Casey; Sherry L Spinelli; Richard P Phipps; Charles W Francis; Neil Blumberg
Journal:  Transfusion       Date:  2012-05-25       Impact factor: 3.157

Review 5.  Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.

Authors:  Jennifer A Frontera; John J Lewin; Alejandro A Rabinstein; Imo P Aisiku; Anne W Alexandrov; Aaron M Cook; Gregory J del Zoppo; Monisha A Kumar; Ellinor I B Peerschke; Michael F Stiefel; Jeanne S Teitelbaum; Katja E Wartenberg; Cindy L Zerfoss
Journal:  Neurocrit Care       Date:  2016-02       Impact factor: 3.210

6.  Multiple levels of degradation diminish hemostatic potential of thawed plasma.

Authors:  Nena Matijevic; Vadim Kostousov; Yao-Wei W Wang; Charles E Wade; Weiwei Wang; Phillip Letourneau; Elizabeth Hartwell; Rosemary Kozar; Tien Ko; John B Holcomb
Journal:  J Trauma       Date:  2011-01

7.  Plasma from chronic liver disease subjects exhibit differential ability to generate thrombin.

Authors:  Zhineng J Yang; Siddharth H Sheth; Chad H Smith; Amy R Schmotzer; Anita L Lippello; Ali Al-Khafaji; Kapil B Chopra; Roy E Smith
Journal:  Blood Coagul Fibrinolysis       Date:  2015-10       Impact factor: 1.276

Review 8.  [Old and new anticoagulants. Antidotes and measures for acute hemorrhaging and urgent interventions].

Authors:  M Lancé; B Stessel; K Hamulyák; M A Marcus
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

9.  Detection of endogenous tissue factor levels in plasma using the calibrated automated thrombogram assay.

Authors:  Veronique Ollivier; Jianguo Wang; David Manly; Kellie R Machlus; Alisa S Wolberg; Martine Jandrot-Perrus; Nigel Mackman
Journal:  Thromb Res       Date:  2009-04-05       Impact factor: 3.944

Review 10.  The new oral anticoagulants and the future of haemostasis laboratory testing.

Authors:  Emmanuel J Favaloro; Giuseppe Lippi
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.